Zinc supplementation enhances the effectiveness of St. Thomas' Hospital no. 2 cardioplegic solution in an in vitro model of hypothermic cardiac arrest  by Powell, Saul R. et al.
ZINC SUPPLEMENTATION 
ENHANCES THE 
EFFECTIVENESS OF ST. 
THOMAS' HOSPITAL NO. 2 
CARDIOPLEGIC SOLUTION 
IN AN IN VITRO MODEL OF 
HYPOTHERMIC CARDIAC 
ARREST 
The present study was done to assess the effectiveness of a zinc-supple- 
mented cardioplegic solution in an in vitro model of hypothermic arrest. 
Isolated hearts were perfused in the nonworking mode. All hearts were 
subjected to 2 hours of hypothermic arrest, at 10 ° C, followed by 60 minutes 
of recovery. In protocol 1, arrest was initiated with infusion of cardioplegic 
solution with or without 30 /~mol/L zinc for 5 minutes, which was then 
reinfused for 5 minutes every 15 minutes during arrest. In protocol 2, arrest 
was initiated with infusion of cardioplegic solution with or without 40 
/tmol/L zinc for 10 minutes. Cardioplegic solution (without zinc) was then 
reinfused for 5 minutes before the hearts were rewarmed. In protocol 1 
hearts, peak postischemic left ventricular developed systolic pressure was 
106 -- 5 mm Hg and 80 ± 3 mm Hg in zinc-treated versus control hearts, 
respectively (p < 0.05 by repeated-measures analysis of variance). In 
protocol 2 hearts, recovery of postischemic left ventrieular developed sys- 
tolic pressure peaked at 74 -+ 4 mm Hg and 46 +- 8 mm Hg in zinc-treated 
and control hearts, respectively (p < 0.05, repeated-measures analysis of 
variance). Similar effects were observed for the left ventricular rate of 
relaxation (p < 0.05, repeated-measures analysis of variance). Except for 
some minor effects, lactate dehydrogenase r lease was not affected by zinc 
supplementation. The present study demonstrates that zinc supplementa- 
tion further enhances the normally observed preservation of postarrest 
cardiac function and suggests possible clinical utility for this metal as an 
additive to standard crystalloid cardioplegic solutions. (J THORAC CARDIO- 
VASC SURG 1995;110:1642-8) 
Saul R. Powell, PhD, a Leslie Aiuto, MD, b Donna Hall, BSc, a and 
Anthony J. Tortolani, MD, a Manhasset, N.Y. 
S ince the development of cardiopulmonary bypass (CPB), the use of cold cardioplegic solutions to 
arrest the heart and decrease myocardial oxygen 
debt has become commonplace. 1 Yet, despite the 
use of these solutions, the occurrence of postoper- 
ative cardiac complications, uch as low-output 
syndrome, continues to be a major problem after 
CPB. z Research in this area has generally focused 
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on the development of more effective chemical 
approaches tomyocardial preservation during CPB. 
The realization that reactive oxygen intermediates 
(ROI) play a role in the postischemic myocardial 
stunning injury 3' 4 began a new era in myocardial 
preservation. Investigators have re soned that the 
postoperative cardiac complications of cardiac op- 
erations that require CPB may in fact represent a
form of myocardial stunning i volving formation of 
ROls. This reasoning isstrengthened by the findings 
of several recent studies in human beings that 
demonstrate he presence of by-products of ROI 
production, such as increased oxidized glutathione, 5 
malondialdehyde, 6 and alkoxyl radicals 7, in post- 
CPB coronary sinus blood. Thus, in both in vitro and 
in vivo experimental models, investigators have at- 
tempted to augment current cardioplegic solutions 
with free radical "scavengers" uch as superoxide 
dismutase and catalase) -1° Despite some early 
promising results, superoxide dismutase has yet to 
find clinical usefulness. 11 The results of one limited 
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clinical study indicated that intravenous uperoxide 
dismutase had no effect on ventricular function in 
patients undergoing thrombolysis because of ante- 
rior wall acute myocardial infarction. 12 
One of the problems with the use of ROI  scaven- 
gers is that they seek to remove the toxic species 
after they are formed. From a kinetic standpoint, it
would seem more advantageous to prevent forma- 
tion of the more reactive species, such as "OH, in the 
first place. In two previous tudies, we demonstrated 
the antiarrhythmic 13 and cardiac protective 14 quali- 
ties of zinc when it is added to Krebs-Henseleit 
buffer in isolated heart models of regional and 
global ischemia. Zinc, a nonredox-active transition 
metal, was tested because of its chemical similarities 
to the redox-active transition metals, iron and cop- 
per. 15 In our previous studies on the globally isch- 
emic heart, a model of stunning, we demonstrated 
that zinc diminished the early reperfusion burst of 
• OH through a mechanism that appeared to be 
related to antagonism of the pro-oxidant activity of 
copper. ~4 Partly on the basis of the success of these 
past studies, we tested the ability of zinc to preserve 
postcardioplegic myocardial function in in vitro 
models of hypothermic and intermittent hypother- 
mic cardioplegic arrest when it is added to a com- 
monly used crystalloid cardioplegic solution. In the 
present study, despite differences in the perfusion 
media and protocols and in the temperature, we 
demonstrate hat zinc maintains its cardioprotective 
qualities even in these models of prolonged hypo- 
thermic arrest. 
Material and methods 
Animals. All studies were conducted in accordance 
with the "Guide for the Care and Use of Laboratory 
Animals" (NIH publication No. 85-23, revised 1985) and 
were approved by the Institutional Animal Care and Use 
Committee of North Shore University Hospital. Male 
Sprague-Dawley rats (275 to 450 gin) were obtained from 
Charles River Laboratory, Inc. (Wihnington, Mass.) or 
Taconic Farms (Germantown, N.Y.) and were allowed at 
least 3 days of in-house acclimatization before experi- 
mental use. During this time, all animals were allowed ad 
libitnm access to Purina Lab Chow (Ralston Purina Co., 
St. Louis, Mo.) and water. 
Chemicals and reagents. Sodium bicarbonate, sodium 
chloride, potassium chloride, HEPES, magnesium sulfate, 
magnesium chloride, d-(+)-glucose, calcium chloride, 
zinc sulfate, and histidine were obtained from Sigma 
Chemical Company (St. Louis, Mo 0. Sodium heparin and 
sodium pentobarbital were obtained from the North 
Shore University Hospital pharmacy. Therapeutic-grade 
95% 02/5% CO2 was obtained from General Welding 
Supply Company (Westbury, N.Y.). 
Table I. Composition of St. Thomas' Hospital 
No. 2 (Plegisol) cardioplegic solution 
Component Concentration (mmol/L) 
Sodium 120.0 
Potassium 16.0 
Calcium 1.2 
Magnesium 16.0 
ChIoride 160.4 
Bicarbonate 10.0 
Perfused heart preparation. Rats were injected with 
sodium heparin (500 units, intraperitoneally) 30minutes 
before being anesthetized with sodium pentobarbital (60 
mg/kg, intraperitoneally). Hearts were removed rapidly 
and placed in ice-cold heparinized saline solution. The 
hearts were then perfused in an orthograde manner 
through the coronary arteries ~6 as previously described ~3 
at a constant pressure of 95 cm H20. 
Perfusate. The perfusate was a modified Krebs-Hense- 
leit buffer consisting of (in millimoles per liter): NaC1 118, 
KC1 6.1, CaCl 2 2.5, MgSO 4 1.2, NaHCO3 25, HEPES 1.0, 
and glucose 11.1. Complete buffer was prepared the day of 
the experiment by mixing the proper amounts of concen- 
trated stock solutions to which the appropriate quantities 
of glucose and calcium chloride were added. All concen- 
trated solutions, with the exception of the magnesium 
sulfate, were treated with iminodiacetic acid chelating 
resin beads, 50 to 100 mesh (Chelex 100, Bio-Rad, 
Hercules, Calif., obtained from Sigma Chemical Co.), as 
previously described) 7 The formula for the cardioplegic 
solution was that of St. Thomas' Hospital No. 2 (Plegisol, 
Abbott Laboratories, Chicago, Ill.) solution is as described 
in Table I and was prepared as a I 0-times concentrated 
solution (without calcium). On the day of the experiment, 
the concentrated solution was diluted and the proper 
amount of calcium added. Zinc was added to the car- 
dioplegic solution as the zinc-bis-histidinate complex (1 
zinc:2 histidines) and was prepared aily. 
Experimental protocols 
Protocol 1. Protocol 1 consisted of intermittent hypo- 
thermic ardioplegia (Fig. 1). Isolated hearts were equil- 
ibrated with Krebs-Henseleit buffer at 37°C for 10 
minutes. During the 2 hours of hypothermic arrest, car- 
dioplegic solution with or without 30 /zmol/L zinc was 
reinfused for 5 minutes every 15 minutes. This was 
followed by 60 minutes of reperfusion with Krebs-Hense- 
leit buffer at 37 ° C. 
Protocol 2. Protocol 2 consisted of "no-flow" hypother- 
mic arrest (Fig. 1). Isolated hearts were equilibrated with 
Krebs-Henseleit buffer at 37°C for 10 minutes. Cardiac 
arrest was initiated with 10 minutes of perfusion with 
cardioplegic solution with or without 40 /xrnol/L zinc at 
10 ° C. During arrest, no cardioplegic solution was infused. 
Just before reperfusion, all hearts were perfused with 
hypothermic ardioplegic solution. Hearts were then 
reperfused for 60 minutes with Krebs-Henseleit buffer at 
37 ° C. 
During arrest cardiac temperature was maintained at 
10 ° C by immersion of the heart in cardioplegic solution 
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Fig. 1. Experimental protocols for cardioplegia studies. 
contained in a thermostatically controlled, water-jacketed 
heart chamber. 
Indices of cardiac function. There were six indicators 
of cardiac function measured in this study. Coronary flow 
was determined by a timed collection of coronary effluent. 
Heart rate was calculated from the R-R interval of the 
electrocardiogram. Left ventricular systolic pressure de- 
velopment and end-diastolic pressure were determined 
by way of a latex balloon (0.1 ml) that was expanded to 
exert a physiologic end-diastolic pressure of 5 mm Hg as 
previously described. 13 Systolic pressure developed or 
pulse pressure was calculated as the peak systolic pressure 
minus the end-diastolic pressure. Contractility was calcu- 
lated as the maximum rate of rise of the pressure curve or 
+dP/dtm~ ~ and the maximum isovolumetrie rate of relax- 
ation was calculated from the rate of fall of the pressure 
curve or -dP/dtma x.
Exclusion criteria. Hearts were excluded from the 
study if they failed to maintain developed systolic pressure 
of at least 70 mm Hg or a heart rate of at least 220 
beats/rain during the 10-minute pretreatment equilibra- 
tion period. Further, hearts were excluded if a persistent 
arrhythmia was present during the equilibration period. 
Chemical analysis. Lactate dehydrogenase (LDH) ac- 
tivity in pulmonary artery effluent was determined with 
use of the method described by Bergmeyer, Bernt, and 
Hess 19 and is expressed in Racker units. 
Statistical analysis. Analysis of differences of cardiac 
functional recovery and LDH release were analyzed with 
a repeated-measures analysis of variance (ANOVA) in 
which the within-group factor was time. Differences 
between two individual groups were analyzed with an 
independent Student's t test. in all cases, results were 
considered to be significant at the p < 0.05 level. All 
statistical analyses were done with the SPSS/PC+ (SPSS 
Inc., Chicago, Ill.) statistical analysis package. 
Results 
Effect on heart rate and coronary flow. The effect 
of zinc-supplemented cardioplegic solutions on 
postischemic heart rate is illustrated in Fig. 2. Treat- 
ment of hearts with zinc according to protocol 1 
resulted in a significantly (p < 0.05, repeated- 
measures ANOVA) lower heart rate in the postcar- 
dioplegia period. By the end of the reperfusion 
period, heart rate in control versus zinc-treated 
hearts had returned to 95% and 80% of precar- 
dioplegic values, respectively. This was not the case 
for protocol 2, because there were no significant 
differences between control and treated hearts with 
this protocol. Heart rate in both groups had re- 
turned to approximately 80% of precardioplegic 
values by the end of the experiment. 
Zinc-supplemented cardioplegic solutions had lit- 
tle effect on coronary flow (data not shown). In 
protocol 1 hearts, the postarrest coronary flow rate 
returned to a peak of 82% of prearrest values 
(control, 17 +_ 1 ml/min; zinc-treated, 16 + 1 
ml/min). In protocol 2 hearts, postarrest coronary 
flow rates returned to a peak of 95% of prearrest 
values (control, 19 + 1 ml/min; zinc-treated, 19 _+ 2 
ml/min). 
Effect on left ventricular systolic pressure devel- 
opment. The effect of zinc-supplemented cardio- 
plegic solutions on postischemic systolic pressure 
development is illustrated in Fig. 3. Treatment of 
hearts with zinc according to both protocols 1 and 2 
resulted in significant (p < 0.05, repeated-measures 
ANOVA, for both protocols) improvement in post- 
cardioplegic left ventricular systolic pressure devel- 
opment. In the protocol 1 groups, maximal recovery 
for zinc-treated hearts was virtually 100%, whereas 
that of control hearts was 80% of preeardioplegic 
values. In the more severe protocol 2 treatment 
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Fig. 2. Effect of zinc-supplemented cardioplegic solution 
on postischemic heart rate. Isolated hearts were equili- 
brated with Krebs-Henseleit buffer at 37 ° C for 10 min- 
utes and then subjected to 2 hours of hypothermic (10 ° C) 
global ischemia. This was followed by 60 minutes of 
reperfusion with Krebs-Henseleit buffer at 37 ° C. A, In- 
termittent hypothermic cardioplegia. Cardiac arrest was 
initiated with 5 minutes of perfusion with cardioplegic 
solution with or without 30 /xmol/L zinc at 10 ° C, which 
was then reinfused for 5 minutes every 15 minutes during 
arrest (control, N = 12; zinc-treated, N = 8). B, "No- 
flow" hypothermic arrest. Cardiac arrest was initiated with 
10 minutes of perfusion with cardioplegic solution with or 
without 40 p, mol/L zinc at 10 ° C. Just before reperfusion, 
all hearts were perfused with hypothermic cardioplegic 
solution (control, N = 9; zinc-treated, N = 7). Statistical 
analysis is presented in Results section. 
groups, maximal recovery was 76% and only 50% in 
zinc-treated and control hearts, respectively. 
Effect on left ventr icular contracti l i ty and rate of 
relaxation. As illustrated in Fig. 4, postischemic 
contractility (+dP/dtm~x) was also improved in the 
zinc-treated hearts. The difference between control 
and treated hearts was significant (p < 0.05, repeat- 
ed-measures ANOVA) in the protocol 1 groups. In 
the protocol 2 groups, because of relatively large 
variability in the control hearts, the difference, while 
apparent, was not significant. Similar, but more 
marked, effects of zinc-supplemented cardioplegic 
solutions were observed on the rate of left ventric- 
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Fig. 3. Effect of zinc-supplemented cardioplegic solution 
on postischemic left ventricular systolic pressure develop- 
ment. Presentation same as in Fig. 2. 
ular relaxation (-dP/dt~ax) (Fig. 5). Differences 
between control and treated hearts were significant 
(p < 0.05, repeated-measures ANOVA) in both 
protocol groups. 
Effect on LDH release. As illustrated in Fig. 6, 
zinc-treatment had virtually no effect on LDH re- 
lease, except for some minor differences (p < 0.05, t 
test) observed toward the end of the reperfusion 
period (protocol 2 only). 
Discuss ion 
The results of this study demonstrate that zinc 
supplementation f a standard cardioplegic solution 
(St. Thomas' Hospital No. 2) further enhances the 
normally observed preservation of postarrest car- 
diac function. One of the most novel aspects of this 
study was that prolonged perfusion with zinc-con- 
taining solutions was not necessary to obtain sig- 
nificant cardiac protection. This is in contrast to 
findings in our previous kinetic studies in the nor- 
mothermic globally ischemic heart. I4 In that study 
we showed that to obtain optimal protection, zinc 
must be present both before and after ischemia. The 
critical period was clearly the preischemic period, 
because treatment at the start of reperfusion only 
actually decreased postischemic recovery. 14 A1- 
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Fig. 4. The effect of zinc-supplemented cardioplegic so- 
lution on postischemic !eft ventricular contractility (+dP/ 
dt .... ). Presentation same as in Fig. 2. 
though zinc is unlike other agents that have been 
tested, such as superoxide dismutase, in that myo- 
cardial cells do absorb zin@ 4 there was some ques- 
tion as to whether sufficient amounts of the metal 
would be available because of the low temperatures 
at which the cardioplegic solution was administered. 
Cellular uptake of zinc is known to be a facilitated 
process that has been demonstrated to be signifi- 
cantly impaired at hypothermic temperatures. 2° 
Yet, despite the need for a critical oading period 
and the possibility of decreased absorption at low 
temperatures, it was thought hat a possible clin- 
ical application of zinc might be myocardial pres- 
ervation during CPB through inclusion in car- 
dioplegic solutions. 
In the present study, two protocols for adminis- 
tration of the cardioplegic solution were examined. 
Protocol 1 represents an in vitro model of intermit- 
tent hypothermic arrest with the total time of per- 
fusion with zinc-supplemented cardioplegic solution 
equaling 35 minutes. Protocol 2 represents a model 
of straight hypothermic arrest, with only 10 minutes 
of perfusion with a higher concentration of zinc at 
the initiation of arrest only. This latter treatment 
interval was chosen because results of previous 
kinetic studies in the global ischemia model sug, 
gested that this period was critical. 14 In both of these 
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Fig. 5. Effect of zinc-supplemented cardiop!egic solution 
on postischemic left ventricular rate of relaxation (-dP/ 
dtm~,). Presentation same as in Fig. 2. 
models, supplementation f the cardioplegic solu- 
tion with zinc resulted in clear improvement of 
'.cardiac function in the postarrest period, particu- 
larly with respect to left ventricular systolic pressure 
development and rate of relaxation. The lower 
postarrest heart rate, observed in protocol 1 hearts, 
is consistent with the negative chronotropic effect of 
zinc that we have previously reported. 13' 14 The 
mechanism of the negative chronotropic effect is 
unclear, but may be related to effects of zinc on 
movement of divalent cations, such as potassium 
and calcium. 21 Effects on heart rate were not ob- 
served in protocol 2 hearts because overall ess zinc 
was administered. On the basis of average coronary 
flow rates, it was estimated that approximately 20 
/,mol of zinc was administered toprotocol 1 hearts, 
whereas only 6/,mol was administered to protocol 
2 hearts. Effects on heart rate do not appear to be 
related to the protective ffect (unpublished obser- 
vations). 
The role of zinc in the heart is not known; how, 
ever, several studies have suggested an increased 
requirement by the postischemic heart. In human 
beings, it has been demonstrated that plasma zinc 
levels decrease after acute myocardial infarc- 
tion. 22-25 In experimentally infarcted og heart, in- 
creased uptake of zinc into the mit0chondri~/and 
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Fig. 6. Effect of zinc-supplemented cardioplegic solution 
on postischemic release of LDH. Presentation same as in 
Fig. 2. 
microsomal fractions, both possible sites of ROI  
production,26, 27has been observed. 28 These results 
suggest an increased need for zinc by the ischemic 
myocardium. Whether the same is true for the 
hypothermic arrested heart, which has decreased 
metabolic oxygen debt, is unclear. Nonetheless, we 
believe that the protection of the heart subjected to 
hypothermic arrest was consistent with that ob- 
served in normothermic globally ischemic hearts t4 
and, further, is consistent with the overall hypothesis 
that zinc is an endogenous antioxidant. 29 We 13' 14, 3o 
and others 31-34 have proposed that zinc inhibits 
site-specific formation of radicals catalyzed by re- 
dox-active transition metals such as iron and cop- 
per. In the crystalloid-perfused isolated heart 
model, the source of the metals appears to be the 
heart itself 14' 35 and possibly Krebs-Henseleit buffer 
under certain conditions, t7 In extracorporeally cir- 
culated blood, during CPB, recent evidence suggests 
that red blood cells may be a potential source of 
both chelatable iron and copper. 36 Zinc, by virtue of 
its similarities in coordination chemistry, Is can dis- 
place site-specifically bound copper or iron, or both, 
though recent evidence suggests that copper is the 
more important of the tVgO. 14'32 Because zinc is 
nonredox active, site-specific formation of radicals 
is thus diminished. Assuming that postoperative 
myocardial dysfunction is indeed a form of iatro- 
genic myocardial stunning injury and that ROIs are 
involved, 5-7 it would be reasonable to suggest hat a 
similar mechanism is involved in the current studies. 
In summary, these studies demonstrate that zinc, 
when added to a cardioplegic solution, can exert a 
protective ffect on the heart in a state of hypother- 
mic arrest, at least in this in vitro crystal!oid- 
perfused isolated heart model, Whether zinc will 
find clinical usefulness as an additive to cardioplegic 
solutions remains to be seen. Clearly, the results of 
this study support the continuation of ongoing in 
vivo large animal studies to confirm the effectiveness 
and safety of zinc as a cardioprotective agent before 
clinical testing in human beings. 
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